Genmab A/S (GMAB) Announces Submissions of Regulatory Applications for Epcoritamab for Relapsed/Refractory LBCL and DLBCL

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. HOOD
10. IBM

Go back to Genmab A/S (GMAB) Announces Submissions of Regulatory Applications for Epcoritamab for Relapsed/Refractory LBCL and DLBCL

AbbVie (ABBV) Falls Following Q3 Release - Softness in US Sales Likely to 'Raise Concerns'

October 28, 2022 9:53 AM EDT

AbbVie (NYSE: ABBV) shares are down more than 5% in early Friday trading after the company reported third-quarter earnings before the open, missing revenue expectations.

The company reported earnings of $3.66 per share, $0.08 better than the analyst estimate of $3.58, while revenue for the quarter came in at $14.81 billion versus the consensus estimate of $14.93 billion.

Following the report, Mizuho Securities analyst Uy Ear told investors in a note... More